Essential Tremor

15
Pipeline Programs
8
Companies
13
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
11
0
3
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
QUDEXY XRApproved
topiramate
Unknown Company
oral2014

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Precision BioSciences
4 programs
3
1
60 mg ulixacaltamidePhase 3
10 mg PRAX-114, 20 mg PRAX-114, and PlaceboPhase 2
100 mg PRAX-944Phase 2
Part A: 20 and 40 mg PRAX-944Phase 2
Praxis Precision Medicines
4 programs
3
1
60 mg ulixacaltamidePhase 31 trial
10 mg PRAX-114, 20 mg PRAX-114, and PlaceboPhase 21 trial
100 mg PRAX-944Phase 21 trial
Part A: 20 and 40 mg PRAX-944Phase 21 trial
Active Trials
NCT05387642Withdrawn0Est. Jun 2022
NCT05021991Completed133Est. Feb 2024
NCT05021978Completed24Est. Mar 2022
+1 more trials
OD
1 program
1
topiramatePhase 3
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
3 programs
3
CX-8998Phase 21 trial
JZP385Phase 21 trial
Sodium OxybatePhase 21 trial
Active Trials
NCT03101241Completed95Est. Jul 2018
NCT05122650Completed420Est. May 2024
NCT00598078Completed19Est. Dec 2008
Biogen
BiogenCAMBRIDGE, MA
2 programs
2
SAGE-217Phase 21 trial
SAGE-324Phase 21 trial
Active Trials
NCT02978781Completed34Est. Dec 2017
NCT05173012Completed146Est. May 2024
Great Lakes NeuroTechnologies
2 programs
Adaptive Portable Essential Tremor MonitorN/A1 trial
Kinesia HomeViewN/A1 trial
Active Trials
NCT01602042CompletedEst. Nov 2012
NCT01978080Completed
Abbott
AbbottABBOTT PARK, IL
1 program
Clinician programmer electrode screening mode toolN/A1 trial
Active Trials
NCT03794661Completed8Est. Dec 2020
BlueWind Medical
BlueWind MedicalIsrael - Herzliya
1 program
Stimulation procedureN/A1 trial
Active Trials
NCT01940406WithdrawnEst. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Praxis Precision Medicines60 mg ulixacaltamide
Praxis Precision Medicines10 mg PRAX-114, 20 mg PRAX-114, and Placebo
BiogenSAGE-324
Jazz PharmaceuticalsJZP385
Praxis Precision Medicines100 mg PRAX-944
Praxis Precision MedicinesPart A: 20 and 40 mg PRAX-944
Jazz PharmaceuticalsCX-8998
BiogenSAGE-217
Jazz PharmaceuticalsSodium Oxybate
AbbottClinician programmer electrode screening mode tool
BlueWind MedicalStimulation procedure
Great Lakes NeuroTechnologiesKinesia HomeView
Great Lakes NeuroTechnologiesAdaptive Portable Essential Tremor Monitor

Clinical Trials (13)

Total enrollment: 1,879 patients across 13 trials

NCT06087276Praxis Precision Medicines60 mg ulixacaltamide

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Start: Nov 2023Est. completion: Dec 20261,000 patients
Phase 3Enrolling By Invitation
NCT05387642Praxis Precision Medicines10 mg PRAX-114, 20 mg PRAX-114, and Placebo

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

Start: Apr 2022Est. completion: Jun 20220
Phase 2Withdrawn
NCT05173012BiogenSAGE-324

Study to Evaluate SAGE-324 in Participants With Essential Tremor

Start: Jan 2022Est. completion: May 2024146 patients
Phase 2Completed
NCT05122650Jazz PharmaceuticalsJZP385

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

Start: Dec 2021Est. completion: May 2024420 patients
Phase 2Completed
NCT05021991Praxis Precision Medicines100 mg PRAX-944

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

Start: Oct 2021Est. completion: Feb 2024133 patients
Phase 2Completed
NCT05021978Praxis Precision MedicinesPart A: 20 and 40 mg PRAX-944

A Clinical Trial of PRAX-944 in Participants With Essential Tremor

Start: Mar 2020Est. completion: Mar 202224 patients
Phase 2Completed
NCT03101241Jazz PharmaceuticalsCX-8998

A Phase 2 RCT Study of CX-8998 for Essential Tremor

Start: Aug 2017Est. completion: Jul 201895 patients
Phase 2Completed
NCT02978781BiogenSAGE-217

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Start: Mar 2017Est. completion: Dec 201734 patients
Phase 2Completed
NCT00598078Jazz PharmaceuticalsSodium Oxybate

Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

Start: Dec 2007Est. completion: Dec 200819 patients
Phase 2Completed
NCT03794661AbbottClinician programmer electrode screening mode tool

Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool

Start: Jun 2019Est. completion: Dec 20208 patients
N/ACompleted
NCT01940406BlueWind MedicalStimulation procedure

The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study

Start: Oct 2013Est. completion: Dec 2013
N/AWithdrawn
NCT01978080Great Lakes NeuroTechnologiesKinesia HomeView

Continuous Tremor Assessment During Daily Activities

Start: Oct 2013
N/ACompleted
NCT01602042Great Lakes NeuroTechnologiesAdaptive Portable Essential Tremor Monitor

Adaptive Portable Essential Tremor Monitor

Start: May 2012Est. completion: Nov 2012
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space